Ankyra is developing anchored immunotherapy that specifically targets cancer cells by enhancing T-cell activation through a novel mechanism. This approach aims to improve treatment efficacy while minimizing adverse effects compared to conventional cancer therapies.
Funding
$59.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic cancer therapies often fail to achieve sufficient drug concentrations within the tumor microenvironment, leading to suboptimal efficacy and dose-limiting toxicities due to off-target effects. Conventional immunotherapies can also trigger systemic immune activation, resulting in immune-related adverse events and limiting their applicability across diverse patient populations.
Solution
Ankyra Therapeutics is developing anchored immunotherapy, a novel approach that enhances T-cell activation specifically within the tumor microenvironment. Their technology utilizes anchored-drug conjugates designed to bind molecules to aluminum hydroxide, improving drug retention within the tumor. This prolonged exposure aims to promote sustained anti-tumor immune responses while minimizing systemic side effects associated with drug leakage. By optimizing drugs with dose-limiting toxicities, Ankyra seeks to improve the therapeutic window and reduce the frequency of dosing required to achieve clinical benefit.
Target Audience
The primary target audience includes patients with advanced solid tumors and the clinicians treating them, as well as pharmaceutical companies seeking to improve the safety and efficacy of their immunotherapeutic agents.
Features
- Anchored-drug conjugates designed for enhanced drug retention in the tumor microenvironment
- Aluminum hydroxide binding to prolong anti-tumor immune activation
- Minimized systemic side effects due to reduced drug leakage
- Potential for less frequent dosing while maintaining therapeutic efficacy
- ANK-101: An IL-12 anchored-drug conjugate currently in clinical trials for advanced solid tumors